{
    "clinical_study": {
        "@rank": "18405", 
        "acronym": "CHANCE-HF", 
        "arm_group": [
            {
                "arm_group_label": "CA125 guided strategy", 
                "arm_group_type": "Experimental", 
                "description": "In this group, physician will be encouraged to maximize all treatment measures aimed to keep CA125\u226435 U/ml (normal values)."
            }, 
            {
                "arm_group_label": "Standard treatment strategy", 
                "arm_group_type": "Active Comparator", 
                "description": "Therapy is based on established european current guidelines"
            }
        ], 
        "brief_summary": {
            "textblock": "Preliminary data suggest a potential role for monitoring and up-titrate pharmacological\n      therapy of plasma levels of antigen carbohydrate 125 (CA125) following and admission for\n      acute heart failure (AHF).\n\n      This study will evaluate the effect of a CA125-guided management strategy versus standard\n      therapy on the composite endpoint of 1-year all-cause mortality or readmission for AHF in\n      patients recently discharged for AHF."
        }, 
        "brief_title": "Carbohydrate Antigen 125-guided Therapy in Heart Failure", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 years or older.\n\n          -  At least 1 admission for AHF, in the last 180 days.\n\n          -  Demonstrates functional New York Heart Association status of Class \u2265II at the moment\n             of enrollment.\n\n          -  Objective evidence, either during the index admission or at least 180 days before\n             enrollment, of a structural or functional abnormality of the heart at rest, and\n             defined as: N terminal-pro-brain natriuretic peptide  >1000 pg/ml or brain\n             natriuretic peptide >100 pg/ml or echocardiographic abnormalities congruent with HF\n             diagnosis such as: systolic left ventricular dysfunction (LVEF <50%); left\n             ventricular hypertrophy (defined as left ventricular septum or left ventricular\n             posterior wall thickness \u226512 millimeters or left ventricular mass  index >104 g/m2 in\n             women or 116 g/m2 in men); Ee`>15 or significant valvular heart disease\n             (moderate-severe).\n\n          -  A plasma CA125 value >35 U/ml in a recent test evaluation (at least 30 days before\n             enrollment, and preferably assessed before hospital discharge).\n\n          -  Patient must be capable of understanding and signing an informed consent form.\n\n        Exclusion Criteria:\n\n          -  Life expectancy <12 months due to other diseases different from HF.\n\n          -  Having undergone a cardiac transplantation, coronary revascularization procedure\n             (percutaneous coronary intervention and/or coronary artery bypass grafting) or\n             cardiac valve replacement in the past 3 months.\n\n          -  Angina pectoris higher than class II (Canadian Cardiovascular Society\n             Classification).\n\n          -  Pregnancy at the moment of enrollment.\n\n          -  Valvular heart disease already scheduled for surgical intervention.\n\n          -  Severe chronic obstructive and/or restrictive pulmonary disease, requiring continuous\n             oxygen administration.\n\n          -  Serum creatinine level > 3 mg/dl or chronic renal insufficiency on dialysis\n             treatment.\n\n          -  Patients receiving resynchronization therapy during the index admission.\n\n          -  Significant concurrent medical diseases including cancer or a history of cancer\n             within 5 years of entering the screening period, endometriosis, cirrhosis, acute\n             coronary syndrome within 6 months, uncontrolled hypertension, history of human\n             immunodeficiency virus (HIV) infection, or a significant active infection.\n\n          -  Participating in another randomized study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02008110", 
            "org_study_id": "EC10-108", 
            "secondary_id": "2011-000414-20"
        }, 
        "intervention": [
            {
                "arm_group_label": "CA125 guided strategy", 
                "description": "Up titration of loop diuretics according to plasma levels of CA125 in the active arm", 
                "intervention_name": "CA125 guided strategy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CA125 guided strategy", 
                "description": "Consider statins in all patients in the active arm", 
                "intervention_name": "CA125 guided strategy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CA125 guided strategy", 
                "description": "Consider omega-3 polyunsaturated fatty acids in the active arm", 
                "intervention_name": "CA125 guided strategy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CA125 guided strategy", 
                "description": "Frequency of monitoring according plasma evolution of CA125 in the active arm.", 
                "intervention_name": "CA125 guided strategy", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Standard treatment strategy", 
                "description": "All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).", 
                "intervention_name": "Standard treatment strategy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CA125 guided strategy", 
                "description": "All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, digoxin, nitrates and vasoactive group).", 
                "intervention_name": "CA125 guided strategy", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Angiotensin-Converting Enzyme Inhibitors", 
                "Angiotensin Receptor Antagonists"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Heart failure", 
            "Biomarker guided-therapy", 
            "Carbohydrate antigen 125", 
            "Clinical outcomes."
        ], 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Valencia", 
                    "country": "Spain", 
                    "zip": "46010"
                }, 
                "name": "Hospital Cl\u00ednico Unbiversitario de Valencia"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Trial of Carbohydrate Antigen 125-guided Therapy Among Patients Recently Discharged for Acute Heart Failure: Effect on 1-year Mortality or Readmission for Acute Heart Failure (CHANCE-HF).", 
        "overall_official": {
            "affiliation": "Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia", 
            "last_name": "Julio N\u00fa\u00f1ez, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Composite of all-cause mortality plus acute heart failure related rehospitalization", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02008110"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia", 
            "investigator_full_name": "Julio N\u00fa\u00f1ez,MD", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Composite of total mortality plus readmission for any cause", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Days alive outside of the hospital", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Number of heart failure rehospitalizations.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Number of episodes of worsening HF not requiring hospitalization", 
                "safety_issue": "No", 
                "time_frame": "1-year"
            }
        ], 
        "source": "University of Valencia", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Ministerio de Sanidad, Servicios Sociales e Igualdad", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Valencia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}